SheMed Secures $50 Million to Expand Women’s GLP-1 Weight Management Platform

London-based women’s healthcare technology company SheMed has raised $50 million in funding to advance its GLP-1-focused weight management and wellness platform. The investment will support the company’s plans to expand its UK footprint, increase its workforce, and accelerate research and patient experience programs. Additionally, the funding will enhance its data-driven care offerings and strengthen its clinical infrastructure.

SheMed’s platform combines diagnostics, telemedicine, and data-driven treatment to offer personalized care for women using GLP-1 medications. The company begins by sending an at-home kit containing a medical profile and blood test. After submission, an independent physician reviews the patient’s results and prescribes a GLP-1 medication suited to their individual health markers. Progress is monitored through weekly app-based check-ins, ensuring continuous engagement and tailored care.

“For more than a decade, I searched for answers to an undiagnosed health issue,” said Olivia Ferro, cofounder and CEO of SheMed. “As a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be. We built SheMed to give women the personalised support I struggled to find: care that listens, understands and empowers.”

The company recently partnered with Tasso, a MedTech firm providing the Tasso+ blood collection device, which SheMed has integrated into its diagnostic kits. Founded in April 2024, SheMed has positioned itself within the rapidly growing digital women’s health market, leveraging data, remote monitoring, and personalized medicine to address unmet needs in weight and metabolic health.

The broader women’s health technology sector continues to expand, with companies such as Wisp, Origin, Maven Clinic, Allara Health, Carrot, and Progyny advancing digital and hybrid care solutions. Notably, Wisp and Origin partnered earlier this year to provide cross-access to reproductive and physical therapy services, while Maven Clinic teamed with Oura to integrate biometric data into its reproductive health platform.

SheMed’s latest funding round underscores growing investor confidence in digital-first women’s health platforms, particularly those integrating precision diagnostics, connected care, and personalized treatment models.

Click here for the original news story.